Notice of Intent to Publish a Funding Opportunity Announcement for Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01)

May 1,2017 | Consortium_staff Funding Opportunities

Posted by: NIH
Post date: April 24, 2017

The National Heart, Lung and Blood Institute (NHLBI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) which will support hybrid effectiveness-implementation trials for heart, lung, blood, and sleep (HLBS) diseases in the inpatient setting. This FOA proposes to support trials testing an implementation strategy (or strategies) aimed at increasing implementation of an evidence-based practice(s).  The intended FOA will seek applications for hybrid effectiveness-implementation trials for HLBS diseases in the inpatient setting. The trial must examine both clinical and implementation outcomes, with a main focus on implementation outcomes. The implementation strategy (or strategies) being tested in the trial must have been developed utilizing an implementation research framework.

Application budgets are limited to $400,000 in direct costs in Year 1 and $675,000 in direct costs in Years 2-5. The maximum project period is 5 years. Foreign components are not allowed except for Canadian components.

Read the full notice for more information.